森林舞会官网

Be the most trusted biotech company

2026-04-24

Henlius' 2025 ESG Report
2026-04-24

Henlius' Phase 2/3 Trial of Pimurutamab (HLX07) in Combination with Serplulimab for Advanced sqNSCLC Completes CTN in Australia
2026-04-23

Henlius Presents Four Hanjugator™ ADCs at AACR 2026, with Multiple Potential Best-in-Class Assets Advancing
2026-04-22

Henlius Showcases HLX3902 Preclinical Data at AACR 2026, Highlighting Its CD28-Enabled Multispecific TCE Platform
2026-04-14

NMPA Grants IND Approval for Henlius' Cetuximab Biosimilar HLX05-N
2026-04-10

Henlius Announces First Patient Dosed in Clinical Trial of HLX319, China’s First Subcutaneous Fixed-Dose Injection of a Pertuzumab/Trastuzumab Biosimilar
2026-04-09

The rituximab with the most approved indications domestically, Henlius' HANLIKANG has obtained approvals for two additional indications
2026-04-01

Enhancing Treatment for Breast Cancer: China’s First Subcutaneous Pertuzumab/Trastuzumab Combination HLX319 Approved for Clinical Trial
2026-03-31

Henlius' Next-Generation rHuPH20 Approved for Clinical Trials, Accelerating Subcutaneous Delivery Platform Development

1
...
3
4
5
6
7
8
...
61